Cigogne Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Cigogne Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$1.15M	Buy	+120,000	New	+$626K	0.68%	51

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Cigogne Management's PSTX Position: Q4 2024 in Review

Cigogne Management opened a new position in Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024: 120,000 shares worth $1.15M. The stake represents 0.68% of the portfolio and ranks #51 among its holdings.

115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Cigogne Management held 120,000 shares of Poseida Therapeutics, Inc. Common Stock worth $1.15M as of Q4 2024.
Poseida Therapeutics, Inc. Common Stock was a new Cigogne Management position in Q4 2024.
Poseida Therapeutics, Inc. Common Stock made up 0.68% of Cigogne Management's portfolio in Q4 2024, its #51 holding.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Cigogne Management's 13F filing for Q4 2024, filed 14 Feb 2025.